Ticker brief
KLRA
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
7
authors 14d
1
crowd 14d
+0.02
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now +0.05 (−1 bearish … +1 bullish)
Who spoke1
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 7 | -0.09 |
Recent signals7of 7 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @bioinvestor24 | +0.05 | Says business-development options are limited and outlines trial and manufacturing timing constraints. | · | tweet ↗ |
| 2026-08-21 | @bioinvestor24 | -0.35 | Raises tolerability concerns about KLRA's dose-escalation design across phase 2 and 3. | · | tweet ↗ |
| 2026-08-21 | @bioinvestor24 | +0.55 | Suggests competitive KLRA data could support commercialization and pressure Novo's options. | · | tweet ↗ |
| 2026-08-18 | @bioinvestor24 | -0.25 | Frames VKTX as a development-timeline leader and assesses obesity-market urgency across major competitors. | · | tweet ↗ |
| 2026-08-16 | @bioinvestor24 | -0.30 | Expresses certainty KLRA and VKTX will not sell for $10 billion, regardless of valuation. | · | tweet ↗ |
| 2026-08-16 | @bioinvestor24 | -0.15 | Raises dosing-practicality and patient-experience concerns for Lilly and KLRA obesity assets. | · | tweet ↗ |
| 2026-08-15 | @bioinvestor24 | -0.15 | Author questions the buyout thesis and management perceptions behind interest in VKTX and KLRA. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.